These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 30788495)
41. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas. Winther TL; Arnli MB; Salvesen Ø; Torp SH Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177 [TBL] [Abstract][Full Text] [Related]
42. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232 [TBL] [Abstract][Full Text] [Related]
43. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker. Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532 [TBL] [Abstract][Full Text] [Related]
44. Utility of PHH3 in Evaluation of Mitotic Index in Breast Carcinoma and Impact on Tumor Grade. Mirzaiian E; Tabatabaei Ghods ZS; Tavangar SM; Emami B; Oraie M; Safyari R; Saffar H Asian Pac J Cancer Prev; 2020 Jan; 21(1):63-66. PubMed ID: 31983165 [TBL] [Abstract][Full Text] [Related]
45. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray. Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351 [TBL] [Abstract][Full Text] [Related]
46. The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index. Tancredi-Cueto N; Vigil-Bastitta G; Bologna-Molina R; Beovide-Cortegoso V Med Oral Patol Oral Cir Bucal; 2022 Sep; 27(5):e444-e451. PubMed ID: 35975799 [TBL] [Abstract][Full Text] [Related]
47. Prognostic importance of mitosis quantification and PHH3 expression in oral epithelial dysplasia. Sathyamoorthy H; Mahmood H; Zubir AZA; Hankinson P; Khurram SA Virchows Arch; 2024 Jan; 484(1):47-59. PubMed ID: 37882821 [TBL] [Abstract][Full Text] [Related]
48. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index. Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143 [TBL] [Abstract][Full Text] [Related]
49. Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas. Samols MA; Smith NE; Gerber JM; Vuica-Ross M; Gocke CD; Burns KH; Borowitz MJ; Cornish TC; Duffield AS Am J Clin Pathol; 2013 Oct; 140(4):579-87. PubMed ID: 24045557 [TBL] [Abstract][Full Text] [Related]
50. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585 [TBL] [Abstract][Full Text] [Related]
51. Anti-phosphohistone H3 (PHH3) as a proliferation marker to assess mitotic activity and to grade neuroendocrine neoplasms of hepatopancreaticobiliary (HPB) system. Santhanam AP; Joel A; Paul A; Zachariah UG; Rebekah GJ; Kodiatte TA Indian J Pathol Microbiol; 2024 Aug; ():. PubMed ID: 39133254 [TBL] [Abstract][Full Text] [Related]
52. Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. Zhang K; Prichard JW; Yoder S; De J; Lin F Hum Pathol; 2007 Jun; 38(6):878-82. PubMed ID: 17350668 [TBL] [Abstract][Full Text] [Related]
53. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574 [TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of phospho-histone H3 in prostate carcinoma. Nowak M; Svensson MA; Carlsson J; Vogel W; Kebschull M; Wernert N; Kristiansen G; Andrén O; Braun M; Perner S World J Urol; 2014 Jun; 32(3):703-7. PubMed ID: 23887713 [TBL] [Abstract][Full Text] [Related]
55. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936 [TBL] [Abstract][Full Text] [Related]
56. PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors. Shin Y; Hyeon J; Lee B; Ha SY; Hong ME; Do IG; Kim KM J Pathol Transl Med; 2015 Jan; 49(1):23-9. PubMed ID: 25812654 [TBL] [Abstract][Full Text] [Related]
57. Classification of follicular lymphoma: the effect of computer aid on pathologists grading. Fauzi MF; Pennell M; Sahiner B; Chen W; Shana'ah A; Hemminger J; Gru A; Kurt H; Losos M; Joehlin-Price A; Kavran C; Smith SM; Nowacki N; Mansor S; Lozanski G; Gurcan MN BMC Med Inform Decis Mak; 2015 Dec; 15():115. PubMed ID: 26715518 [TBL] [Abstract][Full Text] [Related]
58. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Schimming TT; Grabellus F; Roner M; Pechlivanis S; Sucker A; Bielefeld N; Moll I; Schadendorf D; Hillen U Am J Dermatopathol; 2012 May; 34(3):266-9. PubMed ID: 22197861 [TBL] [Abstract][Full Text] [Related]
59. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Wang SA; Wang L; Hochberg EP; Muzikansky A; Harris NL; Hasserjian RP Am J Surg Pathol; 2005 Nov; 29(11):1490-6. PubMed ID: 16224216 [TBL] [Abstract][Full Text] [Related]
60. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas. Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]